Redx to Present Poster on the Potential of RXC008 in Crohn's Disease at the Inammatory Bowel Disease Nordic Conference

Redx (AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and brotic disease, today announces that it will present a poster on the effect of RXC008 in supressing brosis and tissue injury in pre-clinical models of Crohn's disease at the Inammatory Bowel Disease Nordic (IBD Nordic) Conference (23-25 November 2022, Malmo Sweden).

RXC008 is a potent, selective, GI-targeted ROCK1/2 inhibitor currently at pre-IND stage for the treatment of brostenotic Crohn's disease. The poster at IBD Nordic will present results from adoptive transfer and chronic dextran sulphate sodium (DSS) modelling studies which show that RXC008 can suppress brosis and attenuate tissue injury in animal models of GI-brosis and has the potential to be developed as a novel therapy to inhibit brotic stricture formation in Crohn's disease. The results presented in the poster are from a research collaboration between Redx and scientists at Belgium's Ghent University, where noninvasive magnetic resonance imaging (MRI) texture analysis and histology were used in the models to assess reduction in tissue injury and brosis. Redx aims to use MRI translationally in future studies with RXC008 given its ability to monitor the effectiveness of RXC008 without the need for an invasive biopsy.

Contact:

Tel: [phone]

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and brotic diseases, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, being developed as a targeted treatment for Wntdependent cancers, commenced a Phase 2 programme in November 2021. The Company's lead brosis product candidate, the selective ROCK2 inhibitor RXC007, is in development for interstitial lung disease and commenced a Phase 2a trial for idiopathic pulmonary brosis in October 2022. Redx's third drug candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of brostenotic Crohn's disease, is currently in pre-IND stage, with Phase 1 clinical studies expected to commence in 2023.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK inhibitor now in Phase 3 clinical development by Eli Lilly following its acquisition of Loxo Oncology and AZD5055/RXC006, a Porcupine inhibitor targeting brotic diseases including idiopathic pulmonary brosis (IPF), which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals, which includes JZP815, a pan-RAF inhibitor developed by Redx which Jazz is now progressing through Phase 1 clinical studies and an early stage oncology research collaboration.

(C) 2022 Electronic News Publishing, source ENP Newswire